MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Zentalis Pharmaceuticals Inc

Gesloten

1.28 -7.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.22

Max

1.35

Belangrijke statistieken

By Trading Economics

Inkomsten

-7.3M

-47M

Verkoop

27M

27M

EPS

-0.614

Winstmarge

-176.706

Werknemers

166

EBITDA

5.3M

-46M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+351.08% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-11M

130M

Vorige openingsprijs

8.53

Vorige sluitingsprijs

1.28

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 sep 2024, 11:52 UTC

Belangrijke Marktbewegers

Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies

18 jun 2024, 11:59 UTC

Belangrijke Marktbewegers

Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies

Peer Vergelijking

Prijswijziging

Zentalis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

351.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.27 USD  351.08%

Hoogste 10 USD

Laagste 2.2 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Zentalis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

5

Buy

6

Hold

0

Sell

Technische score

By Trading Central

N/A / 1.76Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.